Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Issued Date
2024-01-01
Resource Type
ISSN
21938210
eISSN
21909172
Scopus ID
2-s2.0-85208471627
Journal Title
Dermatology and Therapy
Rights Holder(s)
SCOPUS
Bibliographic Citation
Dermatology and Therapy (2024)
Suggested Citation
Rattanakaemakorn P., Chevaisrakul P., Wongpraparut C., Chiowchanwisawakit P., Tovanabutra N., Tantiwong P., Amornpinyo W., Chakkavittumrong P., Hanvivadhanakul P., Chaiamnuay S., Laodheerasiri S., Pattamadilok B., Choonhakarn C., Mahakkanukrauh A., Aiewruengsurat D., Sangmala S., Pretikul N., Sumethkul K., Satpanich P., Boonsiri M., Sangob N., Asawanonda P. Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study. Dermatology and Therapy (2024). doi:10.1007/s13555-024-01299-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102014
Title
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Author(s)
Rattanakaemakorn P.
Chevaisrakul P.
Wongpraparut C.
Chiowchanwisawakit P.
Tovanabutra N.
Tantiwong P.
Amornpinyo W.
Chakkavittumrong P.
Hanvivadhanakul P.
Chaiamnuay S.
Laodheerasiri S.
Pattamadilok B.
Choonhakarn C.
Mahakkanukrauh A.
Aiewruengsurat D.
Sangmala S.
Pretikul N.
Sumethkul K.
Satpanich P.
Boonsiri M.
Sangob N.
Asawanonda P.
Chevaisrakul P.
Wongpraparut C.
Chiowchanwisawakit P.
Tovanabutra N.
Tantiwong P.
Amornpinyo W.
Chakkavittumrong P.
Hanvivadhanakul P.
Chaiamnuay S.
Laodheerasiri S.
Pattamadilok B.
Choonhakarn C.
Mahakkanukrauh A.
Aiewruengsurat D.
Sangmala S.
Pretikul N.
Sumethkul K.
Satpanich P.
Boonsiri M.
Sangob N.
Asawanonda P.
Author's Affiliation
Ramathibodi Hospital
Siriraj Hospital
Institute of Dermatology Thailand
Chulalongkorn University
Vajira Hospital
Khon Kaen University
Maharaj Nakhon Ratchasima Hospital
Khon Kaen Regional Hospital
Thammasat University
Phramongkutklao College of Medicine
Prince of Songkla University
Rajavithi Hospital
Chiang Mai University
Siriraj Hospital
Institute of Dermatology Thailand
Chulalongkorn University
Vajira Hospital
Khon Kaen University
Maharaj Nakhon Ratchasima Hospital
Khon Kaen Regional Hospital
Thammasat University
Phramongkutklao College of Medicine
Prince of Songkla University
Rajavithi Hospital
Chiang Mai University
Corresponding Author(s)
Other Contributor(s)
Abstract
Introduction: Secukinumab has proven to be effective and safe in psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in the phase 3 studies. However, data on real-world practice is limited. Methods: This study is an ongoing, multicenter, 2-year observational study that focuses on patients with moderate to severe plaque PsO, active PsA, or AS receiving secukinumab. The aim of this study is to present baseline data for the entire study population. Results: A total of 127 patients were enrolled, with 101 having PsO, 12 with PsA, and 14 with AS. Among the patients, approximately 54.0% were male. The mean body mass index ranged from 25.0 to 27.4 kg/m2 across all groups. Patients with PsO had the longest disease duration with an average of 11.0 years, followed by AS (3.0 years) and PsA (1.0 year). Previous biologic therapy was observed in 6.9–8.1% of patients. Baseline disease severity scores revealed moderate to severe disease. In the PsO group, the mean Psoriasis Area and Severity Index score was 16.1. For patients with PsA, the mean Tender Joint Count was 9.1, and the mean Swollen Joint Count was 6.7. In the AS group, the mean Bath Ankylosing Spondylitis Disease Activity Index score was 4.6, and the mean Ankylosing Spondylitis Disease Activity Score was 3.7. Conclusion: The study demonstrates disease durations, disease activity, and treatment history in Thai patients that were generally consistent with previous randomized controlled studies. Long-term data on the efficacy and safety of the treatment will be presented in future publications.